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Drug resistance of clinical and environmental isolates
of Brucella species in Iran: a meta-analysis
Farzad Khademia, Arshid Yousefi-Avarvandb,
Amirhossein Sahebkarc,d,e, Behnam Mohammadi-Ghalehbina,
Mohsen Arzanloua and Hadi Peeridogaheha
Background: Brucellosis is a contagious and febrile disease endemic to Iran. Increased
antibiotic resistance in endemic areasmay lead to increased risk of treatment failure and
the risk of disease relapse. This systematic review and meta-analysis was performed to
determine the antibiotic susceptibility profiles of Brucella species isolated from clinical
and environmental samples in Iran.
Methods: Using national and international databases and extracted keywords from the
MeSH database, a fully computerized search was done until 11 June 2018. Of 385
collected studies on the prevalence of drug resistance of Brucella species isolated in
Iran, six articles were included in the meta-analysis using predefined eligibility criteria.
Results: Overall resistance rates of Brucella species to different antibiotics in Iran were as
follows: doxycycline: 0%, tigecycline: 5.1%, trimethoprim/sulfamethoxazole: 5.7%, cip-
rofloxacin: 2.7%, streptomycin: 5%, rifampin: 9.5%, tetracycline: 4.6%, gentamicin: 3.9%,
moxifloxacin: 0%, erythromycin: 33.3%, azithromycin: 5.8% and ceftriaxone: 6.3%.
Conclusion: Our study revealed that the prevalence of drug resistance of Brucella
species isolated from clinical and environmental samples in Iran was acceptable and
low. However, care should be exercised in the use of common antibiotics for the
treatment of brucellosis to prevent the spread of drug resistance.
Copyright  2018 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Brucellosis, also known as undulant fever or Malta fever, is
a zoonotic disease that severely affects animal and human
health. This disease is caused by a fastidious small Gram-
negative coccobacilli bacteria from the genus Brucella [1].
Infection caused by this intracellular bacterial pathogen is
contagious and variable in severity, and is transmitted to
human from various hosts such as goats and sheep (Brucella
melitensis), swine (Brucella suis) (severe disease), cattle
(Brucella abortus) (mild disease) and dogs (Brucella canis)
(mild disease) [1–3]. Transmission of the disease occurs in
several ways including inhalation, consuming unpasteur-
ized/raw dairy products and contact with infected animal
tissues and is manifested in humans by nonspecific
symptoms such as fever, chills, headache, fatigue, joint
pain, low back pain, back pain, joint pain and body aches
[1–3]. Human brucellosis can be divided into acute and
chronic phases and affects in all age groups, thereby
remaining as a public health issue especially in many
developing countries in the Middle East, Mediterranean
Basin, Southern Europe, North and East Africa,
Southwest and Central Asia and Latin America. However,
the disease has been eradicated in many developed
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countries due to extensive implementation of health and
control programs [3,4]. Brucellosis is endemic in Iran in
both humans and animals, especially in the West and
Northwest regions of Iran [3]. According to the WHO
estimates, more than half a million new cases of
brucellosis occur every year across large parts of the
globe [5]. Incidence of infection in Iran varies between 98
and 130 per 100 000 population [3]. Therefore, treatment
of brucellosis is important in controlling the disease as
well as in preventing relapse, miscarriage and some
complications of brucellosis [6]. The gold standard
antibiotic treatment recommended by WHO that was
presented in 1986 is combination of oral doxycycline and
rifampin for 6 weeks or intramuscular streptomycin for
2–3 weeks [7]. However, new treatment options such as
quinolones (ciprofloxacin or ofloxacin), gentamicin,
trimethoprim-sulfamethoxazole, tetracycline, macrolides
and erythromycin are used to reduce the risk of drug
resistance and treatment failure, reduce the high rate of
recurrence (5–10%) after monotherapy and reduce
serious side effects [7,8]. Similar the regimens are
accepted as the preferred brucellosis treatment in Iran
[8]. Several studies have reported the risk of increased
antibiotic resistance in endemic areas that may lead to
treatment failure and relapse [9].
The aim of the current systematic review and meta-
analysis was to determine the drug resistance pattern of
Brucella species isolated from human and animal samples
in Iran.
Methods
For reporting of systematic reviews and meta-analyses,
the Preferred Reporting Items for Systematic Review
and Meta-Analyses checklist was used [10].
Search strategy
Comprehensive search in national and international
databases including PubMed, Scopus, Google Scholar
and ISI web of knowledge as well as SID (the Scientific
Information Database) and Magiran was performed. The
keywords used to identify English and non-English
studies were ‘drug resistance’ OR ‘antibiotic resistance’
AND ‘Brucella’ AND ‘clinical sample’ OR ‘environmen-
tal sample’ AND ‘Iran’. The last date of search was 11
June 2018. Additional studies were identified by checking
the reference lists of the retrieved articles and hand
searching of journals.
Study selection
After a full electronic search, we established a library
containing studies reporting drug resistance of clinical and
environmental isolated Brucella species in Iran. Identified
cross-sectional studies were selected based on the
eligibility criteria as follows: publication in English or
Persian languages, reporting drug resistance of Brucella
species from clinical and environmental specimens and
limited to Iran.
Data extraction
To obtain all relevant information and avoid data entry
errors, data extractions were performed by two authors.
Authors, year of the study, location of the study, sample
type, specimen type, methods used for bacterial
identification, number of isolated strains, Brucella species
type, methods used for antimicrobial susceptibility testing
and antibiotic resistance rate of bacteria to various used
antibiotics were the main collected data from each of the
included studies. In addition, quality of the selected cross-
sectional studies was performed based on Newcastle-
Ottawa scale (Table 1).
Statistical analysis
To analyze and interpret collected data from included
studies, we used Comprehensive Meta-Analysis software
version 2.2 (Biostat, Englewood, New Jersey, USA).
Depending on the presence or absence of heterogeneity
in the study results, fixed-effects or random-effects
approach was applied to pool the data. The I2 statistic was
used as an index of heterogeneity. An I2 value of less than
25% was considered as ‘low heterogeneity’ suggesting the
use of fixed-effects model (Table 2). Antibiotic resistance
rate of Brucella species collected from human and animal
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Table 1. Quality of the included studies according to the Newcastle-Ottawa scale.
Selectiona Comparabilityb Outcomec
Study
Representativeness
of the sample
Sample
size Nonrespondents
Ascertainment of
the exposure
Comparability of
outcome groups
Assessment of
the outcome
Statistical
test
Irajian et al.       
Irajian et al.       
Asadi et al.       
Farazi et al.       
Rashidi et al.       
Ashrafganjooy et al.       
Razzaghi et al.       
aMaximum 5 stars.
bMaximum 2 stars.
cMaximum 3 stars.
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samples were expressed as percentage and 95% confidence
intervals (95% CIs) in different cities. Finally, evaluating
publication bias was done using funnel plots (Fig. 1).
Results
Figure 2 describes the process for selecting studies using
eligibility criteria. Briefly, a total of 385 studies on the
prevalence of drug resistance of clinical and environmen-
tal isolates of Brucella species were collected from national
and international databases. After reviewing the titles,
abstracts and full texts of articles and removing congress
abstracts, reviews, duplicate publications and articles with
insufficient information, 380 articles were excluded from
the meta-analysis. In addition, one study was included by
checking the reference lists of articles and the meta-
analysis was done with 6 included studies (Fig. 2).
Included studies were conducted in Tehran (two studies),
Hamadan (one study), Markazi (one study), Kurdistan
(one study), Kerman (one study) and Kashan (one study).
As shown in Table 3, disk diffusion, microbroth dilution,
E test and agar dilution were the most widely used
methods for testing the antimicrobial susceptibility of
Brucella species. B. melitensis was the most common
isolated Brucella species in both human and
animal samples.
As shown in Table 2, the prevalence of antibiotic
resistance of Brucella species in both human and animal
168 Reviews in Medical Microbiology 2018, Vol 29 No 4
Fig. 1. Funnel plot of the meta-analysis on the prevalence of antibiotic resistance of Brucella species to rifampin in Iran.
Table 2. Antibiotic susceptibility profile of Brucella species in both human and animal samples in different provinces of Iran.
Antibiotic resistance (%) (95% CI)
Province DOX TIG TMP-SXT CIP STR RIF T GM MXF E AZ CRO
Tehran 0 10.5 (4–
24.9)
3 (0.7–11.1) 0 0 0 6 (0.6–39.3) 6.5 (1.8–
20.4)
ND ND ND ND
Hamadan 0 ND 0 0 0 0 ND 0 0 ND ND ND
Markazi 0 0 10 (3.3–26.8) 6.7 (1.7–23.1) 6.7 (1.7–23.1) 33.3 (19–51.6) 0 0 ND 33.3 (19–51.6) 16.7 (7.1–34.3) 20 (9.3–37.9)
Kurdistan 0 ND ND ND 11.1 (2.8–35.2) 83.3 (59.1–94.5) 0 ND ND ND ND ND
Kerman ND ND 55.6 (25.1–82.3) ND 22.2 (5.6–57.9) 22.2 (5.6–57.9) ND ND ND ND ND ND
Kashan 0 ND 0 0 0 0 ND ND ND ND 0 0
Total 0 5.1 (1.3–
18.2)
5.7 (1.2–22.7) 2.7 (1–7.1) 5 (1.9–12.5) 9.5 (1.9–36.9) 4.6 (1.2–
16.4)
3.9 (1.2–
11.6)
0 33.3 (19–51.6) 5.8 (0.4–51.3) 6.3 (0.3–59.3)
Heterogeneity
I2 (%)
0 33.2 77.5 0 40.4 85.4 39 28.8 0 0 74.2 78
AZ, azithromycin; CIP, ciprofloxacin; CRO, ceftriaxone; DOX, doxycycline; E, erythromycin; GM, gentamicin; MXF, moxifloxacin; ND, not
determined; RIF, Rifampin; STR, streptomycin; T, tetracycline; TIG, tigecycline; TMP-SXT, trimethoprim/sulfamethoxazole.
 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
samples in Iran was as follows: doxycycline (0%),
tigecycline (5.1%; 95% CI: 1.3–18.2), trimethoprim/
sulfamethoxazole (5.7%; 95% CI: 1.2–22.7), ciprofloxa-
cin (2.7%; 95% CI: 1–7.1), streptomycin (5%; 95% CI:
1.9–12.5), rifampin (9.5%; 95% CI: 1.9–36.9), tetracy-
cline (4.6%; 95% CI: 1.2–16.4), gentamicin (3.9%; 95%
CI: 1.2–11.6), moxifloxacin (0%), erythromycin (33.3%;
95% CI: 19–51.6), azithromycin (5.8%; 95% CI: 0.4–
51.3) and ceftriaxone (6.3%; 95% CI: 0.3–59.3).
Discussion
Brucellosis infection is still endemic in Iran and has
imposed economic and public health costs to both
healthcare system and livestock industry [3,8]. In Iran,
similar to other parts of the world, B. melitensis is the
major cause of human brucellosis [16]. Therefore, timely
treatment with single or combined regimens of
antibiotics is pivotal to ensure optimum effectiveness of
the treatment [17].
The major therapeutic regimens used for brucellosis
infection include monotherapy and dual or triple drug
therapy with doxycycline, rifampin, streptomycin and
gentamicin as first-line treatments [16,18]. Several studies
have assessed monotherapy and showed some efficacy and
high relapse rates [6,16]. Nevertheless, in patients with a
low risk of relapse, monotherapy is a cost-effective
alternative regimen [6]. Combination therapy is the most
effective regimen and recommended in many studies
[6,7,16]. In the current study, we found that 100% of
isolated Brucella species in Iran were susceptible to
doxycycline (Table 2). Similar findings were noted in
Egypt, Brazil, Malaysia, Mexico and Peru [9,17,19–21].
Doxycycline is the drug of choice included in various
combination regimens with streptomycin, rifampicin and
gentamicin [7,16]. According to WHO (1986) and
Ioannina (2007) recommendations, doxycycline (6
weeks) and rifampicin (6 weeks) or streptomycin (2–3
weeks) are as first-line regimens for the treatment of
uncomplicated brucellosis [16,18]. Total resistance rate of
Brucella species to rifampicin was low in Iran (9.5%)
(Fig. 3). Studies from Brazil, Mexico and Peru
investigated antibiotic resistance profile and obtained
similar results [17,20,21]. Considering the potential risk
of inducing resistance to rifampicin in some endemic
regions of tuberculosis (TB), using this antibiotic is
challenging especially in Iran where TB and brucellosis
are endemic [22,23]. Therefore, in Kurdistan (83.3%),
Markazi (33.3%) and Kerman (22.2%) provinces of Iran
Antibiotic resistance of Brucella species in Iran Khademi et al. 169
Fig. 2. Study flow diagram.
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where there is a high resistance rate to rifampicin, using
this antibiotic to treat infections is not recommended.
Another valuable anti-TB agent is streptomycin. Similar
to rifampicin susceptibility profile, streptomycin resis-
tance rate in Iran was low (5%). Similar have been
reported in Egypt, Brazil, Malaysia and Mexico
[9,17,19,20]. However, treatment of brucellosis with
streptomycin has some serious side effects including
hearing disorders, nephrotoxicity and toxic effects on the
nervous system and can be limited due to parenteral
administration and streptomycin shortage [8,16]. An
alternative regimen that has been recommended by
WHO for the treatment of brucellosis is tetracycline (6
weeks) and streptomycin (2–3 weeks) [18]. In the current
study, resistance rate of Brucella species to tetracyclines
including tetracycline (4.6%) and tigecycline (5.1%) was
low. Resistance rates were similar to those reported in
Egypt, Malaysia and Mexico [9,19,20].
Second-line regimen recommended by Ioannina for the
treatment of brucellosis is combination of doxycycline (6
weeks) and gentamicin (1 week) [18]. Our study revealed
that 3.9% of Brucella species were resistant to gentamicin in
Iran. Gentamicin resistance rate in Iran was similar to those
reported from Brazil (3.4%) and Malaysia (0%) [17,19].
Therefore, efficacy of these aminoglycoside drugs,
streptomycin and gentamicin, is high against brucellosis
in Iran. Despite the low resistance to both streptomycin and
gentamicin antibiotics in Iran, the use of gentamicin is
preferred for two reasons: first, the wider availability of this
drug and second, to prevent increasing streptomycin
resistance in Iran, an endemic country for TB [16].
In addition, theoptimal treatment regimens recommended
by WHO and Ioannina are cotrimoxazole, ofloxacin and
ciprofloxacin [18]. Cotrimoxazole monotherapy has been
proposed by some sources for children under the age of 8
years and for pregnant women with contraindications for
tetracyclines and quinolones, while WHO recommends
rifampicin monotherapy [18,24]. In Iran, resistance rate of
Brucella species to cotrimoxazole (5.7%) and ciprofloxacin
(2.7%) was low. Therefore, cotrimoxazole is an appropriate
and low-cost alternative in Iran.
New antimicrobial agents such as macrolides are also used
in Iran to decrease the toxic side effects, relapses and drug
resistance associated with commonly used antibrucellosis
drugs [8]. However, resistance rate to erythromycin was
high in Iran (33.3%).
Conclusion
The efficacy of antibiotic regimens for the treatment of
brucellosis is different among various regions of the world.
However, it seems that WHO-recommended regimens are
still efficient in Iran. Based on the results of this meta-
analysis, except erythromycin, resistance rate of Brucella
species to commonly used antibrucellosis drugs in Iran was
acceptable and low. We recommend that identification of
the main mechanisms responsible for the induction of
resistance in Brucella species would be helpful guide the
choice of antibiotics in Iran and other parts of the world.
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Fig. 3. Forest plot of the meta-analysis on the prevalence of antibiotic resistance of Brucella species to rifampin in Iran.
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